DMT and a Shared Alien Universe?

As The New Republic reports, the Colorado-based psychedelics startup Medicinal Mindfulness is currently seeking approval from the Food and Drug Administration to study what it's calling DMTx, an extended-state, intravenous drip version of DMT that will induce in users trips far longer than the roughly five-to-ten minute experiences the drug typically provides.

DMT carries with it a ton of intriguing qualities, including that studies suggest our brains produce the drug naturally and that those who have taken it often experience variations on the same theme: entering what seems to be another plane or dimension replete with its own ethereal beings, sometimes referred to as "machine elves," who are there to welcome them.

Read more

Psilocybin and Bipolar Disorder

Researchers collected survey data from over 500 people with bipolar disorder about their experiences using psilocybin, the results of which were published in a previous paper.

One third of those participants said they experienced “new or increasing symptoms” following psilocybin use, but overall, participants indicated that they believed psilocybin was not harmful.

Read more

Belief Changes with Psychedelics

Johns Hopkins Medicine researchers continue their exploration into psychedelics and how these drugs may produce a wide range of profound changes in perception, cognition and mood.

In a recent study, published on Nov. 1 in the Journal of Psychopharmacology, experts from the Johns Hopkins Center for Psychedelic and Consciousness Research explored belief changes related to psychedelic experiences.

They found that a single psychedelic experience increased a range of nonphysicalist beliefs as well as beliefs about consciousness, meaning and purpose.

Read more

Recent Research on Psilocybin Gives Mixed Results

Compass Pathways published the long awaited results of its phase 2 clinical trial for the treatment of depression with psilocybin–assisted psychotherapy in the New England Journal of Medicine.

Psilocybin showed rapid antidepressant effects for most patients, but only 1 in 5 participants showed significant improvement at 12 weeks.

Read more